annb0t
Top 20
Mesoblast Limited
NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended December 31, 2022.
Dr. Silviu Itescu, Chief Executive of Mesoblast, commenting on the results said, âThere is an urgent need for a therapy that improves the dismal survival outcomes in children with steroid-refractory acute graft vers...
>>> Read more: Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022
NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended December 31, 2022.
Dr. Silviu Itescu, Chief Executive of Mesoblast, commenting on the results said, âThere is an urgent need for a therapy that improves the dismal survival outcomes in children with steroid-refractory acute graft vers...
>>> Read more: Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022
